$RGC #Trending #Nasdaq Regencell Bioscience Holdin
Post# of 7058
HONG KONG, May 16, 2022--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company" , an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM" for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that Yat-Gai Au, the Company’s Chairman and CEO, made purchases of ordinary shares in Regencell ("Ordinary Shares" totaling $5.03 million.
https://finance.yahoo.com/news/regencell-bios...00349.html